EA201890361A1 - Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека - Google Patents

Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека

Info

Publication number
EA201890361A1
EA201890361A1 EA201890361A EA201890361A EA201890361A1 EA 201890361 A1 EA201890361 A1 EA 201890361A1 EA 201890361 A EA201890361 A EA 201890361A EA 201890361 A EA201890361 A EA 201890361A EA 201890361 A1 EA201890361 A1 EA 201890361A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
alkoxy
compounds
tetrahydroisochinolin
haloalkyl
Prior art date
Application number
EA201890361A
Other languages
English (en)
Other versions
EA033057B1 (ru
Inventor
Кайл Дж. Истман
Джон Ф. Кадоу
Кайли И. Парселла
Б. Нарасимхулу Наиду
Тао Ван
Чживэй Инь
Чжонсин Чзан
Original Assignee
ВАЙВ ХЕЛТКЕР ЮКей (№5) ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201890361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ВАЙВ ХЕЛТКЕР ЮКей (№5) ЛИМИТЕД filed Critical ВАЙВ ХЕЛТКЕР ЮКей (№5) ЛИМИТЕД
Publication of EA201890361A1 publication Critical patent/EA201890361A1/ru
Publication of EA033057B1 publication Critical patent/EA033057B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Раскрыты соединения формулы (I), включая фармацевтически приемлемые соли, фармацевтические композиции, содержащие соединения, способы получения соединений и их применение в ингибировании интегразы ВИЧ и лечении инфицированных ВИЧ или СПИД. В соединениях формулы (I) Rвыбран из водорода, алкила или циклоалкила; Rвыбран из тетрагидроизохинолинила и замещен 1 заместителем Rи дополнительно 0-3 галогеновыми или алкильными заместителями; Rвыбран из азетидинила, пирролидинила, пиперидинила, пиперазинила, морфолинила, гомопиперидинила, гомопиперазинила или гомоморфолинила и замещен 0-3 заместителями, выбранными из циано, галогена, алкила, галогеналкила, алкокси и галогеналкокси; Rвыбран из алкила или галогеналкила; Rпредставляет собой алкил; Rвыбран из Ar, (Ar)алкила, (хроманил)алкила, цианоциклоалкила или (дигидробензодиоксинил)алкила; и Arпредставляет собой фенил, замещенный 0-5 заместителями, выбранными из циано, галогена, алкила, циклоалкила, галогеналкила, гидрокси, алкокси, галогеналкокси, (гидрокси)алкокси, (алкокси)алкокси, фенокси, бензилокси, карбокси, фенила и цианоциклоалкила.
EA201890361A 2015-08-11 2016-08-10 Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека EA033057B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11
PCT/IB2016/054832 WO2017025917A1 (en) 2015-08-11 2016-08-10 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
EA201890361A1 true EA201890361A1 (ru) 2018-11-30
EA033057B1 EA033057B1 (ru) 2019-08-30

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890361A EA033057B1 (ru) 2015-08-11 2016-08-10 Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека

Country Status (23)

Country Link
US (2) US10189816B2 (ru)
EP (1) EP3334716A1 (ru)
JP (1) JP6782766B2 (ru)
KR (1) KR20180032649A (ru)
CN (1) CN108137534A (ru)
AR (1) AR105653A1 (ru)
AU (1) AU2016306089B2 (ru)
CA (1) CA2994791A1 (ru)
CL (1) CL2018000363A1 (ru)
CO (1) CO2018001359A2 (ru)
CR (1) CR20180091A (ru)
DO (1) DOP2018000035A (ru)
EA (1) EA033057B1 (ru)
HK (1) HK1249503A1 (ru)
IL (1) IL257240B (ru)
MA (1) MA42614A (ru)
MX (1) MX2018001722A (ru)
PE (1) PE20181002A1 (ru)
PH (1) PH12018500294A1 (ru)
TW (1) TWI657086B (ru)
UA (1) UA120464C2 (ru)
WO (1) WO2017025917A1 (ru)
ZA (1) ZA201800689B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455214A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017195112A1 (en) * 2016-05-11 2017-11-16 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017195113A1 (en) * 2016-05-11 2017-11-16 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3565810A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3565809A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705312C (en) 2007-11-15 2013-06-25 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5269086B2 (ja) 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
JP5285709B2 (ja) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
US8461180B2 (en) 2007-11-16 2013-06-11 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
ES2475970T3 (es) 2009-12-23 2014-07-11 Katholieke Universiteit Leuven Novedosos compuestos antivirales
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US9527842B2 (en) 2013-03-14 2016-12-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2015127003A1 (en) 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3334722A1 (en) * 2015-08-12 2018-06-20 VIIV Healthcare UK (No.5) Limited 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
AU2016306089A1 (en) 2018-03-01
CA2994791A1 (en) 2017-02-16
AU2016306089B2 (en) 2018-08-09
US20180230129A1 (en) 2018-08-16
HK1249503A1 (zh) 2018-11-02
ZA201800689B (en) 2021-08-25
EP3334716A1 (en) 2018-06-20
MA42614A (fr) 2021-05-26
CL2018000363A1 (es) 2018-07-06
PE20181002A1 (es) 2018-06-26
TW201718549A (zh) 2017-06-01
MX2018001722A (es) 2018-05-16
US10189816B2 (en) 2019-01-29
CO2018001359A2 (es) 2018-05-10
IL257240B (en) 2020-02-27
IL257240A (en) 2018-03-29
AR105653A1 (es) 2017-10-25
PH12018500294A1 (en) 2018-08-13
JP2018522927A (ja) 2018-08-16
WO2017025917A1 (en) 2017-02-16
TWI657086B (zh) 2019-04-21
US20190092754A1 (en) 2019-03-28
UA120464C2 (uk) 2019-12-10
DOP2018000035A (es) 2018-03-30
KR20180032649A (ko) 2018-03-30
CN108137534A (zh) 2018-06-08
EA033057B1 (ru) 2019-08-30
JP6782766B2 (ja) 2020-11-11
CR20180091A (es) 2018-06-13

Similar Documents

Publication Publication Date Title
EA201890361A1 (ru) Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
GEP20227428B (en) Heterocyclic compounds as immunomodulators
MX2019000123A (es) Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores.
EA201290260A1 (ru) Бензимидазол-имидазольные производные
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201690760A1 (ru) Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
PH12016501440A1 (en) Novel heterocyclic compounds
EA201592198A1 (ru) Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
MD4800C1 (ru) Соединения аминопиримидинила в качестве ингибиторов JAK
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201690277A1 (ru) Производные замещенного глиоксамидом пирроламида и их применение в качестве лекарственных средств для лечения гепатита b
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU